 Maura Gasparetto
Concepts (226)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aldehyde Dehydrogenase | 8 | 2017 | 99 | 2.080 |
Why?
| | Leukemia, Myeloid, Acute | 10 | 2025 | 683 | 1.570 |
Why?
| | Hematopoietic Stem Cells | 8 | 2017 | 420 | 1.290 |
Why?
| | Cytarabine | 1 | 2019 | 66 | 0.580 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2019 | 105 | 0.560 |
Why?
| | Cation Transport Proteins | 1 | 2019 | 118 | 0.540 |
Why?
| | Flow Cytometry | 8 | 2012 | 1173 | 0.450 |
Why?
| | Hematopoiesis | 3 | 2015 | 194 | 0.440 |
Why?
| | Hematologic Neoplasms | 1 | 2017 | 162 | 0.440 |
Why?
| | Cell Proliferation | 4 | 2019 | 2499 | 0.440 |
Why?
| | Neoplastic Stem Cells | 5 | 2025 | 412 | 0.430 |
Why?
| | Biomarkers, Tumor | 2 | 2019 | 1322 | 0.430 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2025 | 127 | 0.420 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 1048 | 0.410 |
Why?
| | Antigens, Differentiation | 2 | 2012 | 77 | 0.380 |
Why?
| | G1 Phase | 2 | 2012 | 66 | 0.370 |
Why?
| | Adult Stem Cells | 1 | 2012 | 39 | 0.360 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 4 | 2025 | 280 | 0.320 |
Why?
| | Graft Survival | 1 | 2012 | 526 | 0.300 |
Why?
| | Hematopoietic Stem Cell Transplantation | 6 | 2012 | 676 | 0.300 |
Why?
| | Sulfonamides | 4 | 2025 | 581 | 0.280 |
Why?
| | Cell Self Renewal | 2 | 2019 | 53 | 0.270 |
Why?
| | Azacitidine | 2 | 2025 | 157 | 0.250 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 1958 | 0.250 |
Why?
| | B-Lymphocytes | 1 | 2011 | 877 | 0.240 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2017 | 339 | 0.220 |
Why?
| | Retinal Dehydrogenase | 2 | 2017 | 29 | 0.220 |
Why?
| | Antineoplastic Agents | 6 | 2017 | 2197 | 0.210 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2004 | 191 | 0.200 |
Why?
| | Fetal Blood | 2 | 2017 | 342 | 0.200 |
Why?
| | Mice | 13 | 2025 | 18365 | 0.200 |
Why?
| | Prognosis | 4 | 2025 | 4293 | 0.190 |
Why?
| | Lymphoma | 1 | 2004 | 233 | 0.190 |
Why?
| | Reactive Oxygen Species | 2 | 2017 | 621 | 0.180 |
Why?
| | Cell Separation | 5 | 2011 | 307 | 0.170 |
Why?
| | Cells, Cultured | 5 | 2019 | 4155 | 0.170 |
Why?
| | Drug Resistance, Neoplasm | 5 | 2025 | 883 | 0.160 |
Why?
| | Animals | 17 | 2025 | 38109 | 0.160 |
Why?
| | Nuclear Pore Complex Proteins | 2 | 2011 | 40 | 0.150 |
Why?
| | Leukopoiesis | 1 | 2019 | 11 | 0.150 |
Why?
| | Myeloid Progenitor Cells | 1 | 2019 | 17 | 0.150 |
Why?
| | NADPH Oxidase 2 | 1 | 2019 | 35 | 0.150 |
Why?
| | Cytogenetic Analysis | 1 | 2019 | 33 | 0.150 |
Why?
| | Antibodies, Monoclonal | 3 | 2007 | 1524 | 0.140 |
Why?
| | DNA Damage | 2 | 2011 | 430 | 0.140 |
Why?
| | Decision Support Systems, Clinical | 1 | 2022 | 265 | 0.140 |
Why?
| | Tumor Cells, Cultured | 2 | 2019 | 919 | 0.140 |
Why?
| | Protein Kinase Inhibitors | 1 | 2025 | 970 | 0.140 |
Why?
| | Blast Crisis | 3 | 2025 | 35 | 0.140 |
Why?
| | Fusion Proteins, bcr-abl | 3 | 2012 | 69 | 0.130 |
Why?
| | Bone Marrow Cells | 2 | 2017 | 320 | 0.130 |
Why?
| | Blood Cells | 1 | 2017 | 37 | 0.130 |
Why?
| | Arsenicals | 1 | 2017 | 28 | 0.130 |
Why?
| | Oxides | 1 | 2017 | 51 | 0.130 |
Why?
| | Leukemia | 1 | 2019 | 245 | 0.120 |
Why?
| | Recombinant Fusion Proteins | 2 | 2011 | 675 | 0.120 |
Why?
| | Heterografts | 1 | 2017 | 144 | 0.120 |
Why?
| | Isoenzymes | 1 | 2017 | 299 | 0.120 |
Why?
| | Cyclophosphamide | 1 | 2017 | 266 | 0.120 |
Why?
| | Enzyme Inhibitors | 2 | 2013 | 826 | 0.120 |
Why?
| | Mice, Inbred C57BL | 8 | 2019 | 5997 | 0.120 |
Why?
| | Homeodomain Proteins | 2 | 2011 | 524 | 0.110 |
Why?
| | Cell Cycle | 2 | 2011 | 597 | 0.110 |
Why?
| | Animals, Congenic | 2 | 2011 | 9 | 0.110 |
Why?
| | Radiation Chimera | 2 | 2011 | 27 | 0.110 |
Why?
| | Gene Deletion | 2 | 2012 | 389 | 0.100 |
Why?
| | Survival Rate | 1 | 2019 | 2092 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 434 | 0.100 |
Why?
| | Benzaldehydes | 1 | 2013 | 10 | 0.100 |
Why?
| | Neoplasms, Experimental | 1 | 2014 | 173 | 0.100 |
Why?
| | Disulfiram | 1 | 2013 | 15 | 0.100 |
Why?
| | Humans | 20 | 2025 | 144957 | 0.100 |
Why?
| | Myelodysplastic Syndromes | 1 | 2015 | 147 | 0.100 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2014 | 211 | 0.090 |
Why?
| | Piperazines | 2 | 2007 | 381 | 0.090 |
Why?
| | Adenosine Deaminase | 1 | 2012 | 43 | 0.090 |
Why?
| | Tumor Suppressor Proteins | 1 | 2014 | 321 | 0.090 |
Why?
| | Adaptation, Physiological | 1 | 2016 | 570 | 0.090 |
Why?
| | Colony-Forming Units Assay | 1 | 2011 | 95 | 0.090 |
Why?
| | Enzyme Induction | 1 | 2011 | 88 | 0.090 |
Why?
| | Adipose Tissue | 1 | 2016 | 653 | 0.090 |
Why?
| | Lymphopenia | 1 | 2011 | 65 | 0.090 |
Why?
| | Pyrimidines | 2 | 2007 | 533 | 0.090 |
Why?
| | Transcription Factors | 2 | 2011 | 1742 | 0.080 |
Why?
| | Cell Culture Techniques | 2 | 2011 | 375 | 0.080 |
Why?
| | Cell Count | 1 | 2011 | 321 | 0.080 |
Why?
| | Transplantation, Homologous | 1 | 2012 | 415 | 0.080 |
Why?
| | Aldehydes | 1 | 2011 | 142 | 0.080 |
Why?
| | Mice, Knockout | 3 | 2016 | 3125 | 0.080 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 266 | 0.080 |
Why?
| | Mice, Transgenic | 2 | 2014 | 2185 | 0.080 |
Why?
| | Bone Marrow Transplantation | 1 | 2011 | 294 | 0.080 |
Why?
| | Ethanol | 1 | 2015 | 627 | 0.080 |
Why?
| | E2F4 Transcription Factor | 1 | 2009 | 6 | 0.080 |
Why?
| | E2F3 Transcription Factor | 1 | 2009 | 8 | 0.080 |
Why?
| | E2F2 Transcription Factor | 1 | 2009 | 14 | 0.080 |
Why?
| | Cell Lineage | 1 | 2011 | 376 | 0.080 |
Why?
| | Programming Languages | 1 | 2009 | 25 | 0.070 |
Why?
| | E2F1 Transcription Factor | 1 | 2009 | 68 | 0.070 |
Why?
| | Colorectal Neoplasms | 1 | 2017 | 848 | 0.070 |
Why?
| | Telomerase | 1 | 2011 | 248 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2025 | 3550 | 0.070 |
Why?
| | Database Management Systems | 1 | 2008 | 50 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2017 | 4569 | 0.070 |
Why?
| | Information Storage and Retrieval | 1 | 2009 | 121 | 0.070 |
Why?
| | Lymphoma, B-Cell | 1 | 2009 | 132 | 0.070 |
Why?
| | Machine Learning | 2 | 2025 | 587 | 0.070 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2007 | 97 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2009 | 167 | 0.070 |
Why?
| | Graft vs Host Disease | 2 | 2007 | 264 | 0.070 |
Why?
| | Telomere | 1 | 2011 | 288 | 0.070 |
Why?
| | Antigens, CD34 | 2 | 2023 | 88 | 0.070 |
Why?
| | Lymphocytes | 2 | 2007 | 382 | 0.060 |
Why?
| | Rituximab | 2 | 2007 | 210 | 0.060 |
Why?
| | Computer Graphics | 1 | 2007 | 41 | 0.060 |
Why?
| | Artifacts | 1 | 2007 | 139 | 0.060 |
Why?
| | Guidelines as Topic | 1 | 2008 | 268 | 0.060 |
Why?
| | Granulocyte Colony-Stimulating Factor | 2 | 2007 | 89 | 0.060 |
Why?
| | Gene Expression Regulation | 2 | 2011 | 2609 | 0.060 |
Why?
| | Apoptosis | 2 | 2004 | 2430 | 0.060 |
Why?
| | Aphidicolin | 1 | 2004 | 5 | 0.050 |
Why?
| | Phenanthrolines | 1 | 2004 | 8 | 0.050 |
Why?
| | Topotecan | 1 | 2004 | 17 | 0.050 |
Why?
| | Computational Biology | 1 | 2009 | 681 | 0.050 |
Why?
| | Multienzyme Complexes | 1 | 2003 | 67 | 0.050 |
Why?
| | Cysteine Endopeptidases | 1 | 2003 | 73 | 0.050 |
Why?
| | Hydroxamic Acids | 1 | 2003 | 94 | 0.050 |
Why?
| | Leukapheresis | 1 | 2002 | 27 | 0.050 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2002 | 35 | 0.050 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2003 | 220 | 0.040 |
Why?
| | Software | 1 | 2007 | 692 | 0.040 |
Why?
| | Muscle Proteins | 1 | 2003 | 244 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2007 | 2118 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2002 | 161 | 0.040 |
Why?
| | Immunophenotyping | 3 | 2009 | 322 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2002 | 499 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2019 | 202 | 0.030 |
Why?
| | Signal Transduction | 1 | 2011 | 5233 | 0.030 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2017 | 23 | 0.030 |
Why?
| | Stem Cells | 1 | 2002 | 627 | 0.030 |
Why?
| | CD36 Antigens | 1 | 2016 | 32 | 0.030 |
Why?
| | Gonads | 1 | 2016 | 23 | 0.030 |
Why?
| | Cytoprotection | 1 | 2016 | 55 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2019 | 744 | 0.030 |
Why?
| | Lipolysis | 1 | 2016 | 46 | 0.030 |
Why?
| | Risk Assessment | 1 | 2025 | 3676 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2852 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2002 | 1167 | 0.030 |
Why?
| | Imatinib Mesylate | 2 | 2007 | 77 | 0.030 |
Why?
| | Tumor Burden | 1 | 2016 | 322 | 0.030 |
Why?
| | Antigens, CD | 2 | 2009 | 555 | 0.030 |
Why?
| | Benzamides | 2 | 2007 | 224 | 0.030 |
Why?
| | Mice, SCID | 1 | 2014 | 369 | 0.030 |
Why?
| | Genetic Heterogeneity | 1 | 2014 | 62 | 0.030 |
Why?
| | Half-Life | 1 | 2013 | 151 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1718 | 0.020 |
Why?
| | Fatty Acids | 1 | 2016 | 452 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2025 | 8279 | 0.020 |
Why?
| | Adenosine Deaminase Inhibitors | 1 | 2012 | 2 | 0.020 |
Why?
| | Area Under Curve | 1 | 2013 | 331 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2014 | 610 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2016 | 1087 | 0.020 |
Why?
| | Drug Interactions | 1 | 2013 | 401 | 0.020 |
Why?
| | Trans-Activators | 1 | 2014 | 405 | 0.020 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2013 | 139 | 0.020 |
Why?
| | Tamoxifen | 1 | 2012 | 217 | 0.020 |
Why?
| | DNA Primers | 1 | 2012 | 512 | 0.020 |
Why?
| | Female | 5 | 2025 | 78376 | 0.020 |
Why?
| | Transduction, Genetic | 1 | 2011 | 133 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 983 | 0.020 |
Why?
| | Protein Engineering | 1 | 2011 | 122 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2016 | 936 | 0.020 |
Why?
| | Signaling Lymphocytic Activation Molecule Family Member 1 | 1 | 2009 | 2 | 0.020 |
Why?
| | Phospholipase D | 1 | 2009 | 7 | 0.020 |
Why?
| | rhoB GTP-Binding Protein | 1 | 2009 | 4 | 0.020 |
Why?
| | Breast Neoplasms | 1 | 2002 | 2456 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2009 | 88 | 0.020 |
Why?
| | Exodeoxyribonucleases | 1 | 2009 | 28 | 0.020 |
Why?
| | Base Sequence | 1 | 2012 | 2191 | 0.020 |
Why?
| | von Willebrand Factor | 1 | 2009 | 85 | 0.020 |
Why?
| | Indicators and Reagents | 1 | 2008 | 106 | 0.020 |
Why?
| | Miniaturization | 1 | 2007 | 22 | 0.020 |
Why?
| | Cell Division | 1 | 2009 | 766 | 0.020 |
Why?
| | Octamer Transcription Factor-1 | 1 | 2007 | 5 | 0.020 |
Why?
| | Interleukin-3 | 1 | 2007 | 23 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2022 | 11695 | 0.020 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2007 | 43 | 0.020 |
Why?
| | CD8 Antigens | 1 | 2007 | 72 | 0.020 |
Why?
| | Time | 1 | 2007 | 86 | 0.020 |
Why?
| | Quality Control | 1 | 2007 | 163 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2009 | 377 | 0.020 |
Why?
| | Specimen Handling | 1 | 2008 | 186 | 0.020 |
Why?
| | CD3 Complex | 1 | 2007 | 111 | 0.020 |
Why?
| | CD4 Antigens | 1 | 2007 | 139 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2007 | 521 | 0.010 |
Why?
| | Histones | 1 | 2011 | 670 | 0.010 |
Why?
| | Aged | 1 | 2025 | 25947 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2007 | 372 | 0.010 |
Why?
| | Inflammation | 1 | 2016 | 2880 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2007 | 428 | 0.010 |
Why?
| | Cell Survival | 1 | 2007 | 1098 | 0.010 |
Why?
| | Time Factors | 2 | 2007 | 7183 | 0.010 |
Why?
| | Middle Aged | 1 | 2025 | 35928 | 0.010 |
Why?
| | Databases, Factual | 1 | 2009 | 1486 | 0.010 |
Why?
| | Cyclins | 1 | 2003 | 84 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2009 | 1462 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2007 | 1126 | 0.010 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2003 | 112 | 0.010 |
Why?
| | Acetylation | 1 | 2003 | 256 | 0.010 |
Why?
| | Microfilament Proteins | 1 | 2003 | 136 | 0.010 |
Why?
| | Phosphorylation | 1 | 2007 | 1733 | 0.010 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2003 | 159 | 0.010 |
Why?
| | Adult | 1 | 2025 | 40506 | 0.010 |
Why?
| | Male | 2 | 2025 | 72406 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2009 | 1786 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 2007 | 749 | 0.010 |
Why?
| | Pyridones | 1 | 2003 | 199 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2002 | 418 | 0.010 |
Why?
| | Liver | 1 | 2009 | 1888 | 0.010 |
Why?
| | Algorithms | 1 | 2007 | 1839 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2007 | 3415 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2003 | 1258 | 0.010 |
Why?
| | Biomarkers | 1 | 2007 | 4275 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2002 | 2050 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2002 | 1982 | 0.010 |
Why?
| | Phenotype | 1 | 2002 | 3164 | 0.010 |
Why?
|
|
Gasparetto's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|